Biomaterials for the treatment of myocardial infarction

J Am Coll Cardiol. 2006 Sep 5;48(5):907-13. doi: 10.1016/j.jacc.2006.06.005. Epub 2006 Aug 17.

Abstract

For nearly a decade, researchers have investigated the possibility of cell transplantation for cardiac repair. More recently, the emerging fields of tissue engineering and biomaterials have begun to provide potential treatments. Tissue engineering approaches are designed to repair lost or damaged tissue through the use of growth factors, cellular transplantation, and biomaterial scaffolds. There are currently 3 biomaterial approaches for the treatment of myocardial infarction (MI). The first involves polymeric left ventricular restraints in the prevention of heart failure. The second utilizes in vitro engineered cardiac tissue, which is subsequently implanted in vivo. The final approach entails injecting cells and/or a scaffold into the myocardium to create in situ engineered cardiac tissue. This review gives an overview of the current progress in the growing field of biomaterials for the treatment of MI.

Publication types

  • Review

MeSH terms

  • Biocompatible Materials / therapeutic use*
  • Humans
  • Myocardial Infarction / therapy*
  • Polymers
  • Stem Cell Transplantation
  • Tissue Engineering*
  • Ventricular Dysfunction, Left / therapy*

Substances

  • Biocompatible Materials
  • Polymers